Citigroup
NRIX icon

Citigroup’s Nurix Therapeutics NRIX Stock Holding History

Citigroup’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.4M Buy
477,410
+306,308
+179% +$5.08M ﹤0.01% 1660
2025
Q4 		$3.25M Buy
171,102
+163,735
+2,223% +$2.35M ﹤0.01% 2325
2025
Q3 		$68.1K Sell
7,367
-36,360
-83% -$378K ﹤0.01% 4390
2025
Q2 		$498K Sell
43,727
-96,739
-69% -$1.05M ﹤0.01% 3630
2025
Q1 		$1.67M Buy
140,466
+33,116
+31% +$554K ﹤0.01% 2865
2024
Q4 		$2.02M Buy
107,350
+57,757
+116% +$1.32M ﹤0.01% 2809
2024
Q3 		$1.11M Buy
49,593
+22,171
+81% +$502K ﹤0.01% 3183
2024
Q2 		$572K Sell
27,422
-157,358
-85% -$2.45M ﹤0.01% 3305
2024
Q1 		$2.72M Buy
184,780
+169,635
+1,120% +$1.82M ﹤0.01% 2180
2023
Q4 		$156K Sell
15,145
-27,055
-64% -$185K ﹤0.01% 4030
2023
Q3 		$332K Sell
42,200
-4,760
-10% -$43.5K ﹤0.01% 3357
2023
Q2 		$469K Sell
46,960
-66,144
-58% -$675K ﹤0.01% 3421
2023
Q1 		$1M Buy
113,104
+39,508
+54% +$412K ﹤0.01% 2555
2022
Q4 		$808K Sell
73,596
-46,922
-39% -$566K ﹤0.01% 2813
2022
Q3 		$1.57M Buy
120,518
+45,253
+60% +$716K ﹤0.01% 2340
2022
Q2 		$954K Buy
75,265
+50,085
+199% +$568K ﹤0.01% 2701
2022
Q1 		$353K Sell
25,180
-51,431
-67% -$913K ﹤0.01% 3735
2021
Q4 		$2.22M Sell
76,611
-44,041
-37% -$1.34M ﹤0.01% 2546
2021
Q3 		$3.62M Sell
120,652
-1,859
-2% -$57.4K ﹤0.01% 2032
2021
Q2 		$3.25M Buy
122,511
+37,755
+45% +$1.11M ﹤0.01% 2275
2021
Q1 		$2.63M Buy
84,756
+81,242
+2,312% +$3.07M ﹤0.01% 2300
2020
Q4 		$116K Buy
3,514
+2,981
+559% +$98.8K ﹤0.01% 5422
2020
Q3 		$19K Buy
+533
New +$13.4K ﹤0.01% 6240

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Citigroup's NRIX Position: Q1 2026 in Review

Citigroup increased its Nurix Therapeutics (NRIX) stake by 179% in Q1 2026, buying an estimated $5.08M and bringing the position to 477,410 shares worth $7.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1660.

Citigroup first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Citigroup held 477,410 shares of Nurix Therapeutics worth $7.4M as of Q1 2026.
  • Citigroup bought 306,308 Nurix Therapeutics shares in Q1 2026, an estimated $5.08M.
  • Nurix Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #1660 holding.
  • Citigroup first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.